Retinol binding protein 4 levels relate to the presence and severity of coronary artery disease

Nar, Gökay; Sanlialp, Sara Cetin; Nar, Rukiye

doi:10.5937/jomb0-28846

Cited by 4 publications

(3 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Peptidoglycan recognition protein 2 (PGLYRP2) is involved in immunomodulation and innate immunity, while the adenomatous polyposis coli (Apc) gene is crucial in development, negatively regulates Wnt signaling, and may be involved in angiogenesis [64][65][66][67][68][69]. Retinol binding protein 4 (RBP4) is linked to the severity of cardiovascular disorders, and complement factors are known to be associated with hemorrhagic stroke [35,[41][42][43][44][70][71][72][73]. These biomarkers may help in understanding and treating various vascular conditions.…”

Section: Discussionmentioning

confidence: 99%

Circulating Blood Prognostic Biomarker Signatures for Hemorrhagic Cerebral Cavernous Malformations (CCMs)

Croft,

Grajeda,

Aguirre

et al. 2024

IJMS

View full text Add to dashboard Cite

Cerebral cavernous malformations (CCMs) are a neurological disorder characterized by enlarged intracranial capillaries in the brain, increasing the susceptibility to hemorrhagic strokes, a major cause of death and disability worldwide. The limited treatment options for CCMs underscore the importance of prognostic biomarkers to predict the likelihood of hemorrhagic events, aiding in treatment decisions and identifying potential pharmacological targets. This study aimed to identify blood biomarkers capable of diagnosing and predicting the risk of hemorrhage in CCM1 patients, establishing an initial set of circulating biomarker signatures. By analyzing proteomic profiles from both human and mouse CCM models and conducting pathway enrichment analyses, we compared groups to identify potential blood biomarkers with statistical significance. Specific candidate biomarkers primarily associated with metabolism and blood clotting pathways were identified. These biomarkers show promise as prognostic indicators for CCM1 deficiency and the risk of hemorrhagic stroke, strongly correlating with the likelihood of hemorrhagic cerebral cavernous malformations (CCMs). This lays the groundwork for further investigation into blood biomarkers to assess the risk of hemorrhagic CCMs.

show abstract

Section: Discussionmentioning

confidence: 99%

Circulating Blood Prognostic Biomarker Signatures for Hemorrhagic Cerebral Cavernous Malformations (CCMs)

Croft,

Grajeda,

Aguirre

et al. 2024

IJMS

View full text Add to dashboard Cite

show abstract

“…Peptidoglycan recognition protein 2 (PGLYRP2) is involved in immunomodulation and innate immunity, while the adenomatous polyposis coli (Apc) gene is crucial in development, negatively regulates Wnt signaling, and may be involved in angiogenesis [90][91][92][93][94][95] . Retinol binding protein 4 (RBP4) is linked to the severity of cardiovascular disorders, and complement factors are known to be associated with hemorrhagic stroke 61,[67][68][69][70][96][97][98][99] . These biomarkers may help in understanding and treating various vascular conditions.…”

Section: Discussionmentioning

confidence: 99%

Blood prognostic biomarker signatures for hemorrhagic cerebral cavernous malformations (CCMs)

Croft

Grajeda

Abou‐Fadel

et al. 2023

Preprint

View full text Add to dashboard Cite

Background: Cerebral cavernous malformations (CCMs) is a neurological disorder that causes enlarged intracranial capillaries in the brain, leading to an increased risk of hemorrhagic strokes, which is a leading cause of death and disability worldwide. Objectives: The current treatment options for CCMs are limited, highlighting the need for prognostic biomarkers to predict the risk of hemorrhagic events to better inform treatment decisions and identify future pharmacological targets. Eligibility Criteria: The study is centered on a comparative proteomic analysis between hemorrhagic CCMs (HCs) and healthy controls, while excluding patients with non-hemorrhagic CCMs (NHCs) from the analysis due to the experimental design. Sources of Evidence: Recent research has identified several serum biomarkers and blood circulating biomarkers in a selected cohort of homogeneous CCM patients and animal models. Method: Proteomic profiles from both human and mouse CCM models were examined, and pathway enrichment analyses were performed using three approaches (GO, KEGG, and DOSE). To account for multiple comparisons, t-tests were employed to evaluate differences. A p-value below 0.05 was deemed statistically significant. Results: The authors have developed the first panel of candidate biomarker signatures, featuring both etiological and prognostic markers in two distinct pathways. This panel of biomarker signatures demonstrates a robust correlation with the likelihood of hemorrhagic CCMs. Conclusions: This groundbreaking biomarker panel paves the way for further investigation of potential blood biomarkers to determine the risk of hemorrhagic CCMs.

show abstract

“…Furthermore, survival analysis was conducted for AMI patients, and the results showed that AMI patients in high concentration group had a prominently shorter survival time than those in low concentration group. A large amount of extracellular visfatin can release numerous inflammatory factors, which causes the rupture of unstable atheromatous plaques, increases the incidence rate of adverse cardiovascular events in AMI patients and distinctly shortens the survival time of the patients [17] . Atrial fibrillation is currently one of the most common types of persistent arrhythmia in clinic, and PCI-induced atrial fibrillation is closely associated with AMI, whose risk can be reduced remarkably by administration with anticoagulants and antiplatelet agents [18] [19] .…”

Section: Discussionmentioning

confidence: 99%

Correlations of visfatin with severity of acute myocardial infarction, cardiovascular risk factors and atrial fibrillation after percutaneous coronary intervention

Zhang¹,

Lei²,

Zhang³

et al. 2023

J Med Biochemistry

View full text Add to dashboard Cite

Background: To investigate the relationship between visfatin level in the peripheral blood of patients with acute myocardial infarction (AMI) patients and the severity of AMI, cardiovascular risk factors and atrial fibrillation after percutaneous coronary intervention (PCI). Methods: A total of 37 AMI patients diagnosed and treated in our hospital were selected as experimental group, and 35 patients with normal coronary angiography were enrolled as control group. The general pathological data and occurrence of atrial fibrillation after PCI of all the patients were recorded in detail, and the content of indexes related to the severity of AMI and visfatin was measured. Moreover, the correlations of visfatin with the severity of AMI, cardiovascular risk factors and atrial fibrillation after PCI were explored. Results: The differences in the levels of N-terminal pro-B-type natriuretic peptide (NT-proBNP), cardiac troponin I (cTnI), myoglobin (MYO) and creatine kinase isoenzyme MB mass (CK-MBm) in the peripheral blood, left ventricular end-systolic diameter (LVEDs), left ventricular end-diastolic volume (LVEDV) and left ventricular ejection fraction (LVEF) were statistically significant between experimental group and control group. Furthermore, experimental group had a remarkably higher visfatin level in the peripheral blood than control group. The visfatin level in the peripheral blood was positively correlated with the severity of AMI and the cardiovascular risk factors, but it was negatively associated with atrial fibrillation after PCI. Conclusion: The visfatin level in the peripheral blood of AMI patients has close correlations with the severity of AMI, cardiovascular risk factors and atrial fibrillation after PCI.

show abstract

Retinol binding protein 4 levels relate to the presence and severity of coronary artery disease

Cited by 4 publications

References 23 publications

Circulating Blood Prognostic Biomarker Signatures for Hemorrhagic Cerebral Cavernous Malformations (CCMs)

Circulating Blood Prognostic Biomarker Signatures for Hemorrhagic Cerebral Cavernous Malformations (CCMs)

Blood prognostic biomarker signatures for hemorrhagic cerebral cavernous malformations (CCMs)

Correlations of visfatin with severity of acute myocardial infarction, cardiovascular risk factors and atrial fibrillation after percutaneous coronary intervention

Contact Info

Product

Resources

About